24
Participants
Start Date
May 31, 2015
Primary Completion Date
September 30, 2017
Study Completion Date
October 31, 2017
PF-05082566
Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
KW-0761
Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
Georgetown University Medical Center, Washington D.C.
Georgetown University, Washington D.C.
Medstar Georgetown University Hospital, Washington D.C.
UNC Cancer Hospital Infusion Pharmacy, Chapel Hill
Moffitt Cancer Center and Research Institute, Tampa
Tennessee Oncology, PLLC, Gallatin
Tennessee Oncology, PLLC, Nashville
The Sarah Cannon Research Institute, Nashville
Cleveland Clinic Taussig Cancer Institute, Cleveland
Cleveland Clinic, Cleveland
Henry Ford Hospital Research Pharmacy, Detroit
Henry Ford Hospital, Detroit
Sanford Cancer Center, Sioux Falls
Sanford Research, Sioux Falls
Sanford USD Medical Center, Sioux Falls
UC San Diego Medical Center - La Jolla(Thornton Hospital), La Jolla
University Of California / San Diego Moores Cancer Center, La Jolla
University of California San Diego Moores Cancer Center, La Jolla
UC San Diego Medical Center - Hillcrest, San Diego
UC San Diego Moores Cancer Center, La Jolla
UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
Lead Sponsor
Kyowa Kirin Co., Ltd.
INDUSTRY
Pfizer
INDUSTRY